tumor necrosis factor receptor superfamily member 17; CD269; B-cell maturation protein (TNFRSF17, BCM, BCMA, CD269)
Jump to navigation
Jump to search
Function
- receptor for TNFSF13B/BLyS/BAFF & TNFSF13/APRIL
- promotes B-cell survival
- role in regulation of humoral immunity
- activates NF-kappa-B & JNK
- associates with TRAF1, TRAF2, TRAF3, TRAF5 & TRAF6
Structure
contains 1 TNFR-Cys repeat
Compartment
- single-pass type 3 membrane protein
- plasma membrane, endomembrane system
- perinuclear Golgi-like structures
Expression
- expressed in mature B-cells & plasma cells, including multiple myeloma cells
- not expressed in T- cells or monocytes
Pathology
- chromosomal translocation t(4;16)(q26;p13) involving TNFRSF17 with IL2 is found in T-cell acute lymphoblastic leukemia (T-ALL)
Pharmacology
- target for multiple myeloma CAR T-cell therapy[2]
More general terms
References
- ↑ UniProt http://www.uniprot.org/uniprot/Q02223.html
- ↑ 2.0 2.1 Fuerst ML CAR T-Cell Therapy Shows Durable Activity in Heavily Pretreated Multiple Myeloma. B-cell maturation antigen most promising myeloma target for CAR T-cell therapy. MedPage Today. ASCO Reading Room. Feb 1, 2018 https://www.medpagetoday.com/reading-room/asco/immunotherapy/70885
Cohen AD, Garfall AL, Stadtmauer EA et al 505 Safety and Efficacy of B-Cell Maturation Antigen (BCMA)- Specific Chimeric Antigen Receptor T Cells (CART-BCMA) with Cyclophosphamide Conditioning for Refractory Multiple Myeloma (MM). ASH 59th Annual Meeting. Dec 9-12, 2017 https://ash.confex.com/ash/2017/webprogram/Paper106279.html - ↑ NIEHS-SNPs http://egp.gs.washington.edu/data/tnfrsf17/